Moleculin Biotech, Inc. filed a Form 8-K on November 4, 2026, disclosing that an abstract featuring data from its lead drug candidate, Annamycin, has been accepted for presentation at the 2026 American Society of Hematology Annual Meeting.

Key Highlights

  • Abstract accepted: An abstract highlighting data from Annamycin, Moleculin Biotech's lead drug candidate, has been accepted for presentation at the 2026 ASH Annual Meeting, according to the filing.
  • Conference dates: The 2026 ASH Annual Meeting is scheduled to take place December 12-15, 2026, the filing disclosed.
  • Conference location: The meeting will be held in New Orleans, Louisiana, per the filing.
  • Disclosure type: The information was furnished under Item 7.01 (Regulation FD Disclosure) and is not deemed "filed" under the Securities Exchange Act of 1934.
  • Exchange listing: Moleculin Biotech's common stock, par value $0.001 per share, trades on NASDAQ:MBRX, as stated on the filing's cover page.

Moleculin Biotech Reports Annamycin Abstract Accepted for ASH 2026 Presentation

On November 4, 2026, Moleculin Biotech, Inc. issued a press release announcing that an abstract highlighting data from Annamycin, its lead drug candidate, has been accepted for presentation at the 2026 American Society of Hematology Annual Meeting. The company disclosed this development through a Form 8-K filed with the U.S. Securities and Exchange Commission on the same date, under Item 7.01 (Regulation FD Disclosure).

According to the filing, the ASH Annual Meeting is scheduled for December 12-15, 2026, in New Orleans, Louisiana. The press release announcing the abstract acceptance is attached to the report as Exhibit 99.1 and is incorporated by reference in the filing. Moleculin Biotech is headquartered at 5300 Memorial Drive, Suite 950, Houston, TX 77007, as stated in the filing.

The filing specifies that the information furnished under Item 7.01, including Exhibit 99.1, "shall not be 'filed' for the purpose of the Securities Exchange Act of 1934" and shall not be incorporated by reference in any filing under the Exchange Act or Securities Act of 1933 "unless specifically identified therein as being incorporated by reference." The report was signed by Jonathan P. Foster on behalf of Moleculin Biotech, Inc.

What Was Disclosed

Moleculin Biotech filed an 8-K on November 4, 2026, disclosing that an abstract featuring data from its lead drug candidate, Annamycin, was accepted for presentation at the ASH Annual Meeting scheduled for December 12-15, 2026, in New Orleans, Louisiana.